The Life Sciences team advised iTeos Therapeutics, Inc. (Nasdaq: ITOS) on its initial public offering of 10,586,316 shares of common stock at a public offering price of $19.00 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by iTeos, are expected to be approximately $201.1 million. In addition, iTeos has granted the underwriters a 30-day option to purchase up to an additional 1,587,947 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
iTeos is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients.
The Goodwin team was led by Mitchell Bloom, Danielle Lauzon, Stephanie Richards, Christopher Huntsman, Brittany Morreale, Kaitlin Carragher.
For more details, read the press release and articles in FierceBiotech, MarketWatch, and Boston Business Journal.
iTeos is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients.
The Goodwin team was led by Mitchell Bloom, Danielle Lauzon, Stephanie Richards, Christopher Huntsman, Brittany Morreale, Kaitlin Carragher.
For more details, read the press release and articles in FierceBiotech, MarketWatch, and Boston Business Journal.